The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC).
 
Charlton Tsai
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Tiago Biachi de Castria
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly O.; MDHealth Brasil; Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly O.; Merck Sharp & Dohme
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly O.; Merck Sharp & Dohme
 
Laura H. Tang
Honoraria - Astellas Scientific and Medical Affairs Inc
 
David H. Ilson
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly/ImClone; Macrogenics; Merck; Roche/Genentech; Taiho Pharmaceutical
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Apexigen; AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb; I-Mab; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Adaptimmune (Inst); Arog (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CARsgen Therapeutics (Inst); Daiichi Sankyo (Inst); Merck (Inst); Oncolys BioPharma (Inst); Pieris Pharmaceuticals (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals
 
Nikolaus Schultz
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - AmerisourceBergen; Arcus Biosciences; AskGene Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Imedex; Imugene; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Steven Brad Maron
Stock and Other Ownership Interests - Calithera Biosciences
Honoraria - Clarion Healthcare; Clinical Care Options; Medpage; Physicans' Education Resource; Practicing Clinician Exchange; Vindico Medical Education
Consulting or Advisory Role - Amgen; Bicara Therapeutics; Daichi Sankyo; Elevation Oncology; Novartis
Research Funding - Epic Sciences; Guardant Health (Inst)